Hotel booking aggregator Trivago, which last month admitted to breaching the consumer laws over its travel accommodation rankings, has lost a bid to keep secret internal documents that detail why the company made changes to its website and rejigged its advertising.
Three former executives of failed Gold Coast finance company MFS Group have lost their challenge to a ruling that they misappropriated $147.5 million in funds prior to the company’s collapse.
Law firm Squire Patton Boggs is taking a fight over a ruling that shut down its shareholder class action against logistics startup GetSwift to the High Court.
The consumer watchdog has sought more than $1.5 million in penalties against debt collector ACM Group after the company was found liable for harassing vulnerable customers, but a judge on Tuesday questioned whether the fine, which could leave the company insolvent, was too punitive.
The Commonwealth has urged the court to strike out the “inconsistent” pleadings of pharmaceutical firms Otsuka and Bristol-Myers Squibb in a patent case over the antipsychotic drug Abilify, calling them a “scandal” which could bring disrepute to the administration of justice.
A shareholder class action led by Bannister Law against sandalwood oil producer Quintis will be absorbed by rival law firm Gadens in a consolidation agreement that ends a battle over the competing cases.
Hastie Group’s liquidators have offered to drop their $124 million case against two dozen major builders if the companies agree to pay an undisclosed sum toward their unpaid bills, a court heard Friday.
The director of property spruiker We Buy Houses has appealed a record $6 million for misleading property investors with claims they could learn to buy real estate for $1.
The former managing director of Murray Goulburn will be hit with a $200,000 penalty for being knowingly concerned in false representations made by the dairy producer to farmers about the farmgate milk prices it would pay during the 2015-16 milk season.
Pharmaceutical giant Wyeth has accused Merck Sharp & Dohme of a “baseless” patent invalidity case, saying on the second day of trial over the world’s best selling vaccine that the development of its patented Prevnar 13 pneumococcal shot was anything but obvious, as its rival contends.